- Home
- BPMC
as 05-30-2025 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.8B | IPO Year: | 2015 |
| Target Price: | $125.88 | AVG Volume (30 days): | 789.4K |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $73.04 - $121.90 | Next Earning Date: | 05-01-2025 |
| Revenue: | $562,121,000 | Revenue Growth: | 99.19% |
| Revenue Growth (this year): | 44.49% | Revenue Growth (next year): | 33.04% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 5 '25 | Sell | $103.62 | 2,752 | $283,818.52 | 16,944 | |
| Haviland Kate | BPMC | CHIEF EXECUTIVE OFFICER | Apr 1 '25 | Sell | $86.89 | 2,498 | $216,460.72 | 166,029 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 24 '25 | Sell | $95.02 | 2,274 | $216,075.48 | 69,266 | |
| Albers Jeffrey W. | BPMC | Director | Mar 12 '25 | Sell | $88.00 | 7,500 | $658,500.00 | 152,396 | |
| Albers Jeffrey W. | BPMC | Director | Mar 5 '25 | Sell | $88.80 | 5,766 | $512,020.80 | 152,396 | |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 5,284 | $469,219.20 | 72,924 | |
| Lee Philina | BPMC | CHIEF COMMERCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 3,733 | $331,490.40 | 41,996 | |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Mar 5 '25 | Sell | $88.80 | 5,157 | $457,941.60 | 49,606 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 5 '25 | Sell | $88.80 | 6,495 | $576,756.00 | 69,266 | |
| Namouni Fouad | BPMC | PRESIDENT, R & D | Mar 5 '25 | Sell | $88.80 | 6,489 | $576,223.20 | 75,781 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
TipRanks
8 days ago
‘Stay Invested’: Wells Fargo Suggests 2 Stocks to Ride the Market Recovery
Simply Wall St.
10 days ago
3 High Growth Tech Stocks In The US Market
MT Newswires
24 days ago
Blueprint Medicines Insider Sold Shares Worth $283,819, According to a Recent SEC Filing
Simply Wall St.
a month ago
Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates
Simply Wall St.
a month ago
Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
a month ago
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
GuruFocus.com
a month ago
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...
Thomson Reuters StreetEvents
a month ago
Q1 2025 Blueprint Medicines Corp Earnings Call
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.